Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764110 · ClinicalTrials.gov registry record · NA
Short-term Impact of Cyplexinol® on Self-reported Joint Pain
A NA study, sponsored by University of Memphis.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04764110: Completed NA study, sponsored by University of Memphis.
NCT04764110 is a NA study that has completed, run by University of Memphis. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04764110, a NA study, has completed, sponsored by University of Memphis.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the two hour after subjects ingest a single dosage of Cyplexinol® or placebo on days 1 and 15.
Primary Outcome
TNF-alpha measured in blood
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Cyplexinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-01-28 |
| Phase | NA |
What the finished NCT04764110 record still lists
NCT04764110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04764110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04764110 about?
NCT04764110 is a clinical study titled "Short-term Impact of Cyplexinol® on Self-reported Joint Pain". In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the t...
What is the current status of trial NCT04764110?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2021-03-17. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04764110?
The interventions under investigation include: Placebo (OTHER), Cyplexinol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04764110?
This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04764110's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI